Diphtheria remains a significant health risk requiring consistent vaccination

Diphtheria, an infection caused by the bacterium Corynebacterium diphtheriae, represents a persistent global health concern. While the disease was once a widespread cause of childhood mortality, the development and deployment of the diphtheria toxoid vaccine in the early 20th century transformed it into a rare occurrence in much of the developed world. However, medical experts maintain that because the bacterium remains present in various regions, the disease is capable of re-emerging if vaccination coverage rates are permitted to decline.

Clinical Presentation and Risks

Infection typically begins between two and five days after exposure, often manifesting as a sore throat, fever, and fatigue. In severe instances, the infection leads to the development of a pseudomembrane—a tough, leathery grey or white patch that forms in the throat or nose. This coating can obstruct the airway, leading to a condition historically associated with a barking cough. The bacteria produce an exotoxin that can enter the bloodstream, potentially causing life-threatening systemic complications, including myocarditis, kidney failure, and paralysis resulting from nerve inflammation. In cases where the toxin reaches critical levels, the mortality rate for untreated individuals can reach 40–50%. Even with medical intervention, the disease remains lethal for 5–10% of those diagnosed, with fatality rates rising to 20% among children under five and adults over 40.

Because the diphtheria toxin binds rapidly to tissues, medical professionals emphasize the necessity of immediate administration of antitoxin based on clinical suspicion rather than waiting for laboratory confirmation, as the antitoxin cannot neutralize toxin that has already bound to body tissues. Treatment also involves the use of antibiotics like erythromycin or benzylpenicillin to manage the infection, though these do not accelerate the healing of local tissue damage caused by the toxin.

The Evolution of Vaccination Strategy

Prevention relies on the diphtheria toxoid, an inactivated form of the bacterial toxin. Modern immunization schedules commonly utilize combination vaccines, such as DTaP for children and Tdap or Td for adolescents and adults. Global health organizations, including UNICEF, employ pentavalent vaccines in developing regions to address diphtheria alongside other conditions like tetanus, pertussis, hepatitis B, and haemophilus influenzae type b. To maintain protection, health authorities recommend booster doses every 10 years. The success of these measures is documented in historical trends: in the United States, cases fell significantly following the adoption of widespread vaccination in the 1930s. Conversely, historical records indicate that in areas where isolation and treatment were prioritized over active immunization, such as in parts of Germany during the late 1930s, incidence rates saw marked increases.

Regional Healthcare Frameworks

Within the United Kingdom, the delivery of preventative health services and immunisation programmes operates through the NHS, which functions as a confederation of four distinct systems in England, Scotland, Wales, and Northern Ireland. Research into the historical funding of these services reveals long-standing disparities in per capita allocations, often influenced by the Barnett formula and historical administrative processes rather than strictly by variations in clinical need. For instance, data from the mid-1990s showed that Scotland received significantly higher funding per capita than England, which facilitated higher rates of inpatient and outpatient activity and lower workloads for medical staff.

Ongoing Surveillance and Next Steps

Public health bodies continue to track the disease, which remains most prevalent in regions of sub-Saharan Africa, South Asia, and Indonesia. Monitoring the global landscape serves as a reminder of the persistence of Corynebacterium diphtheriae.

• Booster Compliance: Adults who have not received a diphtheria booster within the last decade should contact their local clinic to verify their current immunity status.
• Clinical Vigilance: Medical providers continue to maintain protocols for rapid diagnosis and the immediate availability of antitoxin, as early intervention remains the primary determinant of patient survival in the event of an outbreak.